Company intelligence / Profile preview
China Pharmaceutical Research & Development Center
Chinaen.phirda.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has a pipeline of at least five programs, including small molecules and herbal medicines. Its most advanced asset is in Phase 2 for angina. Other assets are in Phase 1 or IND approval stages, targeting indications such as venous thrombosis, primary dysmenorrhea, non-small cell lung cancer with EGFR mutation, and chronic urticaria
- Therapeutic areas
- OncologyCardiovascularDermatologyWomen's Health
- Modalities
- Small moleculeHerbal medicineChemical drug
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on China Pharmaceutical Research & Development Center.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharmaceutical Research & Development Center.